# Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

> **NCT06334133** · PHASE3 · RECRUITING · sponsor: **vTv Therapeutics** · enrollment: 150 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Cadisegliatin 800 mg QD
- **DRUG:** Cadisegliatin 800 mg BID
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06334133
- **Lead sponsor:** vTv Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-14
- **Primary completion:** 2026-09
- **Final completion:** 2026-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06334133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06334133, "Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06334133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*